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Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia (AML) often associated with a poor
prognosis. It is more frequent in elderly patients, limiting the use aggressive therapies. Azacitidine is a
hypomethylating agent with recognized efﬁcacy in high risk myelodysplasia and AML in the elderly. Here
we report 5 cases of AEL treated with Azacitidine. The cohort included 4 men and 1 woman, median age
70. One patient had been refractory to intensive chemotherapy, the others received Azacitidine as ﬁrst
line. Treatment was well tolerated. Four patients achieved transfusion independence. Two patients
achieved complete remission and 1 achieved partial remission. After a median follow up time of 20
months, the median survival of the cohort was 20 months. Three patients died of disease progression.
These results conﬁrm the therapeutic value of Azacitidine in AEL.
& 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Acute erythroleukemia (AEL) is a rare subtype of acute myeloid
leukemia (AML), accounting for 3–5% of all AML cases1. It is char-
acterized by the expansion of erythroblasts in the bone marrow
(BM)2,3. Its clinical presentation often resembles myelodysplastic
syndromes (MDS), both in terms of indolent cytopenias2 and older
median age at diagnosis of 654. High risk karyotypes, with hypodi-
ploidy, complex alterations (including abnormalities of chromo-
somes 5 and 7) and monosomies are frequent1. Consequently, AEL is
associated with poor prognosis, with a median survival of 3–9
months from diagnosis4.
It is traditionally treated with intensive chemotherapy, achiev-
ing rates of complete remission (CR) of approximately 55% but
these last less than a year1. As in other AML subtypes, patients
with high risk cytogenetics should be considered for allogeneic
bone marrow transplant1. However, the fact that most patients are
elderly and frail means that aggressive treatment options are often
not possible, limiting management to supportive care.
In the last few years hypomethylating agents have become the
ﬁrst line therapy for patients with MDS and AML who are not
candidates for aggressive chemotherapy, including bone marrow
transplantation5. Azacitidine has demonstrated to grant patients
with high risk MDS and AML with 20–30% blasts a survival
advantage compared to conventional care regimens6.
There are several reports of use of Azacitidine in AEL, including
a series of 17 patients, where CR was achieved in 58%, mediant (A. Almeida).
-NC-ND license.disease free survival of 11 months and median survival of 12
months7.
Here we report a case series of ﬁve patients with AEL diagnosed
at our institution and treated with Azacitidine (AZA).
Although the standard AZA administration schedule is
75 mg/m2/day for 7 days every 28 days (757), at our institution,
due to lack of availability of weekend administration and patient
travel constraints, we adopted an alternate dose-intensiﬁed schedule
over a shorter period of time (500 mg/m2 total monthly dose divided
in 5 days) with daily dose adjustment in order to avoid weekend
administration and vial wastage. Using this regimen in high risk MDS
patients we have observed similar efﬁcacy and safety proﬁles as
those published with the 757 schedule.
1.1. Patient population
Between 2009 and 2012, 6 patients with AEL classiﬁed accord-
ing to WHO 2008 criteria were diagnosed at our institution. Five
patients were treated with AZA. The median age at presentation
was 70 and most patients were men. All patients presented with
transfusion dependent anemia, requiring a median of 3 units
packed red blood cells per month. Poor risk karyotype was found
in 3 patients.
The presentation features are detailed in Table 1.
All patients apart from patient 1 received Azacitidine as ﬁrst line
therapy. Patient 1 received one course of intensive chemotherapy, to
which the disease was refractory, prior to starting Azacitidine.
Azacitidine was administered subcutaneously as a ﬁve-day regi-
men (500 mg/m2 total dose divided in 5 administrations) with daily
dose adjustment to the nearest 100 mg repeated every 4 weeks.
Patients received supportive care at the physician's discretion.
Marrow response was assessed following the 6th treatment cycle.
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Marrow remission was documented in 2 patients and partial
remission in one patient. Three patients achieved transfusion
independence after a median of 4 cycles. Table 2 details the
responses achieved with Azacitidine.
All patients were treated until disease progression apart from
patient 1, who received an unrelated bone marrow transplant at
the end of 16 cycles of Azacitidine. A mean of 10 cycles (1–17) of
Azacitidine were administered per patient.
Treatment with Azacitidine was well tolerated. Grade 1/2
toxicities, seen in all patients, were local injection site erythema,
constipation, neutropenia and thrombocytopenia, the latter seen
mostly in the ﬁrst 4 cycles. There were no admissions to hospital
during the treatment period and there were no treatment suspen-
sions due to adverse events.
In this small cohort with a median follow up time of 25.9
months the median survival from diagnosis was 26 months. If the
patient who underwent transplant is censored, the median survi-
val was 22 months. At the time of data collection, three patients
had died, all of disease progression.2. Discussion
AEL is a rare subtype of AML commonly associated with
previous myelodysplasia, complex karyotype and poor prognosis.
Conventional treatment options are often limited, raising the need
for novel approaches. Azacitidine, licensed for use in high risk
MDS, has demonstrated efﬁcacy in a small series of AEL patients7.
Here we presented the results of Azacitidine in ﬁve patients
diagnosed with AEL.Table 1
Patient characteristics at presentation.
Age Gender Hb
(g/dL)
Neutrophils
(109/L)
Platelets
(109/L)
1n 62 Male 8.0 0.4 60
2 65 Male 7.7 1.3 673
3 73 Female 8.0 1.0 113
4 70 Male 9.5 1.1 30
5 76 Male 6.8 0.2 124
Hb: hemoglobin; BPH: benign prostatic hypertrophy; DM: diabetes mellitus.
n Patient 1 received prior intensive chemotherapy.
nn Calculated in non-erythroid component.
Table 2
Responses with Azacitidine.
Cycles AZA
received
Best hematological
response
Time to ﬁrst response
(cycles)
1n 16 Transfusion
independence
4 (TI)
2 17 Transfusion
independence
5 (TI)
3 9 No response 6 (marrow PR)
4 1 No response –
5 9 Transfusion
independence
4 (TI)
AZA: Azacitidine; CR: complete remission; PR: partial remission; TI: transfusion indepe
n Patient 1 received prior intensive chemotherapy.Our report differs from the only other published report of
hypomethylating agents in erythroleukemia7 in several aspects.
Our patient group is more uniform: all patients were treated with
AZA as monotherapy compared to 35% who were treated with
decitabine and 30% who received concomitant histone deacetylase
inhibitors. The proportion receiving AZA as second line therapy
was similar to that previously published7. The response rate was
similar but treatment duration and overall survival in our cohort
were longer: 10 cycles compared to 5 cycles and median survival
of 22 months compared to 12 months.
Treatment was administered on an outpatient basis, for 5 days
every 28 days, providing a good quality of life for the patients.
Therapy was well tolerated, with minimal toxicity. None of the
patients required admission for febrile neutropenia and or drug
interruption for grade 3–4 toxicities.
Transfusion independence was achieved in all the patients. Two
patients achieved marrow remission and one achieved a partial
remission, all of which lasted over 18 months.
The favorable results obtained with the 5-day schedule raise
the question of whether patients with AEL respond better to a
dose intensiﬁed regimen. This would need to be veriﬁed in a larger
cohort, preferably in the context of a trial.
In patient 1, who had been refractory to intensive chemother-
apy, Azacitidine permitted disease control for over 1 year during
the search for a compatible bone marrow donor and preparation
for SCT. Reduced intensity conditioning regimens have opened the
option of SCT to more elderly and frail patients but the toxicities
associated with conventional intensive AML induction chemother-
apy can increase the risk of death or compromise SCT. It has been
shown recently that Azacitidine before SCT does not signiﬁcantly
affect rates of remission, relapse, acute and chronic GVHD andPercentage
of marrow
blastsnn
Karyotype Comorbidities
36 46,XY,del(5)(q15q?31)[5]/46,XY[20] Obesity, cholecytitis, BPH
17.5 46XY[20] Ischemic heart disease
33 48,XX,+1, del(5)(q13q3334) or del
(5)(q15q35),+11, +18,-22[8]/48,
idem,add(21)(p1?3)[2]/46,XX[2]
None
25 46,XY,del(5)(q13q33 or q15q35)[10]/
46,XY[14]
None
40 46,XY,del(5)(q1?4q3?3)[15]/46,XY,
−7,+mar[1]
DM type II
Marrow response
at 6th cycle
Survival (months from
start of therapy)
Survival (months
from diagnosis)
Marrow CR 28+ 29+
CR 19 20
PR 24+ 25+
Not applicable 2 4
Stable 16 24
ndence.
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inducing remission in patients with high risk MDS and eventually
AEL9.
The results from this cohort conﬁrm the therapeutic value of
Azacitidine in AEL, with improvement in TI, maintenance of
autonomous daily activities and permitting a curative approach
in those who are transplant candidates. Large, prospective clinical
trials are needed to conﬁrm these results and to establish the use
of hypomethylating agents in AEL.Acknowledgments
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